Investment Thesis
SLNO demonstrates exceptional financial strength with $133M cash, excellent liquidity (5.62x current ratio), and strong profitability margins (33.2% net margin). However, negative gross profit is a critical concern requiring clarification on cost structure, production ramping, or revenue mix changes in the pharmaceutical sector.
Strengths
- Exceptional balance sheet with 495.8M equity and low leverage (0.10x debt/equity)
- Strong operating margins of 33.1% with positive net income of 31.4M and growing EPS
- Excellent liquidity position: 5.62x current ratio, 133M cash, and 25.9M positive free cash flow
- Conservative capital structure with 24.2x interest coverage ratio and minimal capex requirements
Risks
- Negative gross profit of -38K with 0.0% gross margin is highly unusual for pharma and indicates structural cost issues
- Revenue growth of 13,024% YoY is unsustainable and suggests one-time event (product launch, acquisition, milestone)
- Modest returns on capital (ROE 6.3%, ROA 5.2%) suggest capital deployment inefficiency despite strong absolute earnings
- Pharmaceutical sector exposure carries inherent regulatory, clinical, and commercial execution risks
Key Metrics to Watch
- Gross profit margin sustainability and recovery trajectory
- Revenue growth normalization and organic growth rate going forward
- Return on equity and return on assets improvement with revenue scale
- Operating cash flow trend relative to net income and capital allocation decisions
Financial Metrics
Revenue
94.6M
Net Income
31.4M
EPS (Diluted)
$0.59
Free Cash Flow
25.9M
Total Assets
608.4M
Cash
133.0M
Profitability Ratios
Gross Margin
0.0%
Operating Margin
33.1%
Net Margin
33.2%
ROE
6.3%
ROA
5.2%
FCF Margin
27.4%
Balance Sheet & Liquidity
Current Ratio
5.62x
Quick Ratio
5.32x
Debt/Equity
0.10x
Debt/Assets
18.5%
Interest Coverage
24.21x
Long-term Debt
49.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T12:24:31.260476 |
Data as of: 2026-03-31 |
Powered by Claude AI